Mepiprazole

Mepiprazole (INN, BAN) (brand name Psigodal) is an anxiolytic drug of the phenylpiperazine group with additional antidepressant properties^[1] that is marketed in Spain.^{[2][3][4][5][6]} It acts as a 5-HT_2A and α₁-adrenergic receptor antagonist^[7][8][9] and inhibits the reuptake and induces the release of serotonin, dopamine, and norepinephrine to varying extents,^[1][9] and has been described as a serotonin antagonist and reuptake inhibitor (SARI).^[10]

Mepiprazole

Clinical data
Trade names	Psigodal
Other names	PAP; EMD-16923; H-4007
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name 1-(3-Chlorophenyl)-4-[2-(5-methyl-1H-pyrazol-3-yl)ethyl]piperazine
CAS Number	20326-12-9 20344-15-4 (hydrochloride)
PubChem CID	71897
ChemSpider	64909
UNII	977BAL0NR7
CompTox Dashboard (EPA)	DTXSID30174223
Chemical and physical data
Formula	C16H21ClN4
Molar mass	304.82 g·mol−1
3D model (JSmol)	Interactive image
SMILES Cc3cc(CCN2CCN(c1cccc(Cl)c1)CC2)n[nH]3

Usages

Controlled clinical trials of mepiprazole in patients with irritable bowel syndrome (IBS) were also carried out and suggested some benefits of the drug in relieving symptoms of IBS in some patients.^[11] Similarly to other phenylpiperazines like trazodone, nefazodone, and etoperidone, mepiprazole produces mCPP as an active metabolite.^[12]

See also

• Acaprazine
• Enpiprazole
• Lorpiprazole
• Tolpiprazole